▶주메뉴 바로가기
▶본문 바로가기
Celltrion announced Wednesday that its metastatic colorectal and breast cancer drug, Vegzelma, has become the most prescribed bevacizumab in Europe, demonstrating strong growth in its market share. According to market research firm IQVIA, Vegzelma accounted for 29 percent of bevacizumab-adcd prescriptions in Europe as of the third quarter of 2024. This marks a 9 percentage point increase from the previous quarter after its market debut in October 2022. Despite entering the market later than some
Daewoong Pharmaceutical announced Monday that its smart patient monitoring system, thynC (Think Better, Sync Smarter), has become the first domestically developed digital health care device in Korea to receive insurance reimbursement approval. The company held a press conference in central Seoul, where it introduced its broader digital health care vision, aiming to establish a more efficient and cost-effective medical checkup system for both patients and hospitals. Cho Byung-ha, head of Daewoong
Celltrion announced on Friday that its biosimilar Avtozma, a version of the autoimmune disease treatment Actemra (active ingredient tocilizumab), has received product approval from the US Food and Drug Administration. Based on the results of its global Phase 3 clinical trial, Celltrion applied for Avtozma's FDA approval last year. The approval covers major indications, including rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic
South Korea's leading drugmaker Daewoong Pharmaceutical announced on Friday that it has officially launched its botulinum toxin product Nabota in Saudi Arabia, the largest market for the neurotoxin medication in the Middle East. The launch comes after the drugmaker received product approvals from the US Food and Drug Administration, the European Medicines Agency and Health Canada, reinforcing Nabota’s global credibility and quality. Saudi Arabia, the largest economy in the Middle East, is seeing
For Korean investors and companies looking to engage with California’s dynamic life science sector, Biocom California Honorary President Joe Panetta assured that the association offers a wealth of resources to create abundant opportunities for cross-country collaboration and innovation. "We want to find partners and work in hubs that bring opportunity to our members to expand their business and access to capital," Panetta said during a press briefing held Wednesday in San Francisco on the sideli
SAN FRANCISCO ― Lotte Biologics CEO James Park unveiled the firm’s new platform for antibody-drug conjugates, a promising class of anticancer drugs, as its biopharmaceutical production facility in the US is getting ready to welcome its first client. At the JP Morgan Healthcare Conference's Asia-Pacific sessions on Thursday, the pharmaceutical unit of Lotte Group introduced its proprietary and innovative ADC platform, SoluFlex Link, and announced plans to provide one-stop ADC services in collabor
SAN FRANCISCO -- Heirs to Korea’s leading conglomerates stepped onto the global biopharma stage at this year’s JP Morgan Healthcare Conference, highlighting their ambitions in the pharmaceutical and biotech sectors. At the conference held Monday through Thursday in San Francisco, key figures including Seo Jin-seok of Celltrion, Shin Yoo-yeol of Lotte Biologics, and Chey Yoon-chung of SK Biopharmaceuticals, underscored their companies’ commitment to future growth by building connections with part
SAN FRANCISCO -- Samsung Biologics has made a major move into the antibody-drug conjugate market, announcing that its newly constructed 500-liter ADC-dedicated production facility will commence operations this February. Joseph Jeong, vice president of the ADC Development Team at Samsung Biologics, highlighted the rationale behind the expansion, emphasizing the company’s ability to leverage its established expertise in monoclonal antibody CDMO services to advance ADC therapeutics. "Samsung Biolog
SAN FRANCISCO ― Hanmi Pharmaceutical is poised to bring a new chapter to obesity treatment, a topic that has garnered significant attention at this year’s JP Morgan Healthcare Conference. Despite the spotlight on obesity drugs, industry concerns remain about potential side effects such as nausea, vomiting and overall muscle loss, which could lead to further complications for patients. Choi In-young, senior vice president and head of Hanmi Pharmaceutical's R&D Center, expressed confidence in the
Samsung Group's biotech arm aims for major capacity boost, adding 720,000 liters through its second bio campus by 2032 SAN FRANCISCO-- Samsung Biologics CEO John Rim unveiled the company's strategy to ascend as a top-tier biopharmaceutical company, grounded in its "4E (Excellence)" approach, unveiled at the JP Morgan Healthcare Conference held in San Francisco, on Tuesday. The 4E framework encompasses the values that Samsung Biologics' employees embody: customer excellence, operational excellenc
Despite strong 2024, Shinhan Financial’s profit dips in Q4
Use of facial recognition grows in Korean finance, with Toss in lead
Top hotel chains eye Hilton Seoul redevelopment
LG CNS posts record profit in 2024
LG CNS becomes Korea’s first SAP Asia-Pacific strategic services partner
KB Financial logs industry's first W5tr annual earnings